Back to search results

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

BRAF V600E · Colorectal Cancer · Sintilimab · MSS (Microsatellite Stable) · Cetuximab · Dabrafenib · Ipilimumab N01

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Peking union medical college hospital, Beijing, Beijing Municipality, China

    Contact: Study coordinator (Xicheng Wang, Prof.) · xicheng_wang@hotmail.com · 010-69158370

  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    Contact: Study coordinator (Zhenyu Lin) · whxhlzy@hust.edu.cn · 027-85871982

  • West China Hospital Sichuan University, Chengdu, Sichuan, China

    Contact: Study coordinator (Meng Qiu, MD) · qiumeng33@hotmail.com · 028-85423203

  • Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China

    Contact: Study coordinator (Ting Deng, PhD) · 18526812877@163.com · +86 18526812877
View source on ClinicalTrials.gov(opens in a new tab)